A 61-year-old woman presented with solitary lymphadenopathy suspicious for lymphoma. An excisional biopsy of a right inguinal lymph node demonstrated metastatic Merkel cell carcinoma (MCC). No skin lesions were detected, but a primary nasopharyngeal mass was identified. A microscopic examination of the nasopharyngeal tumor and the lymph node metastasis showed a monotonous population of small-to intermediate-sized, round blue cells with vesicular nuclei, finely granular and dusty chromatin, and multiple nucleoli. Immunohistochemistry showed perinuclear dot-like staining for cytokeratins AE1/AE3 and CK20. Microscopic appearance and immunohistochemical stains were consistent with MCC. MCC was recently shown to harbor a novel polyomavirus, Merkel cell polyomavirus (MCPyV), in the majority of cases. In this case, MCPyV was detected in the primary tumor and metastasis using polymerase chain reaction and CM2B4 immunohistochemical stain. This is the first report to demonstrate the presence of MCPyV and CM2B4 in a mucosal MCC and its metastasis.
Introduction
Merkel cell carcinoma (MCC) is rare malignant tumor with a marked tendency for local recurrences, lymph node metastasis, and hematogenous spread. 1 Although occurring most commonly in the skin, MCC has been reported to occur in sun-protected sites such as the oral and nasal mucosa, vulva, and penis. [2] [3] [4] [5] This aggressive epithelial cancer is uncommon but increasing in frequency. Approximately 1500 new MCC cases are diagnosed in the United States each year. 6 During the period 1986 to 2001, the incidence rate tripled, and the average annual increase was 8%. 7 Both male and female rates have increased significantly, with the rates in men almost 3-fold higher than in women. MCC of the skin is more common in older people, with age-specific rates highest in the seventh decade, and 95% of MCC cases arise in individuals older than 50 years. 8 MCC is more common in lighter-skinned individuals and is associated with a history of sun exposure, occurring predominantly in sun-exposed areas such as the face and extremities. 9 MCC has been linked to immune suppression, and 8% of MCC patients are chronically immunosuppressed, presenting a 16-fold increase over the general population. 10 Such patients have organ transplants, B cell lymphomas, and AIDS. [11] [12] [13] In 2008, Feng et al 14 reported the identification of a polyomavirus in MCC by digital transcriptome subtraction. It was named Merkel cell polyomavirus (MCPyV). DNA sequences from this virus were detected in 8 of 10 MCC specimens but in only 4 of 25 (16%) control skin and non-MCC skin tumor samples from immunocompetent and immunosuppressed patients and in 5 of 59 (8%) control tissue samples from various body sites (including 9 skin samples) from patients without MCC. In 6 of 8 MCPyV-positive MCCs, viral DNA was integrated within the tumor genome, suggesting that MCV infection preceded clonal expansion of the tumor cells. These findings indicate that MCPyV is not only directly associated with MCC but that it may be the oncogenic agent. Here, we report a unique case of mucosal MCC harboring the MCPyV and the presence of MCPyV in both the primary mucosal tumor and lymph node metastasis.
Case Report
A 61-year-old woman with a past medical history of hypertension, bipolar disorder, obstructive sleep apnea, and chronic obstructive pulmonary disease presented with solitary lymphadenopathy, clinically suspicious for lymphoma. An enlarged right inguinal lymph node was biopsied and showed a small-cell neoplasm whose histology and immunophenotype were consistent with metastatic MCC. The patient denied ever having skin lesions, and none were detected on clinical examination. Bronchoscopy and a CT of the chest showed no evidence of tumor. The patient later presented with hemoptysis and worsening dyspnea. A CT scan revealed a large nasopharyngeal mass narrowing the oropharyngeal airway. Following surgical removal, the mass was diagnosed as MCC. Treatment with etoposide, cisplatin, and radiation was instituted.
Pathological Findings Histology, Immunohistochemistry, and Flow Cytometry
The microscopic examination of the nasopharyngeal tumor and the lymph node metastasis showed a monotonous population of small-to intermediate-sized, round cells with vesicular nuclei, finely granular and dusty chromatin, and multiple nucleoli ( Figure 1 ). Table 1 depicts the results of the immunohistochemical stains performed on both the primary tumor and metastasis. Immunohistochemistry revealed perinuclear staining in a dot-like pattern with cytokeratins AE1/AE3 (N1590, Dako Corporation, Carpinteria, CA), CK20 (N1627, Dako Corporation), and TdT (760-2670, Ventana Medical Systems, Tucson, AZ). Tumor cells were diffusely positive for C-KIT (A4502, Dako Corporation) and chromogranin (N1535, Dako Corporation) and negative for LCA (N1514, Dako Corporation), S-100 (N173, Dako Corporation), CD99 (760-2631, Ventana Medical Systems), TTF-1 (790-4398, Ventana Medical Systems), and CK7 (760-2224, Ventana Medical Systems). The flow cytometry results for the right inguinal lymph node and nasopharyngeal mass revealed no evidence of B-cell monoclonality or aberrant antigen expression.
Molecular Analysis
Monoclonal antibody CM2B4 (IgG2b isotype) was generated by standard hybridoma technologies and by immunizing mice with (KLH)-derivatized SRSRKPSSNASRGA peptide from the MCV T-antigen exon 2 with a C-terminal cysteine (Epitope Recognition Immunoreagent Core Facility, University of Alabama, AB). 15 Both the primary tumor and lymph node metastasis had strong nuclear immunoreactivity to monoclonal antibody CM2B4 (1:2000 hybridoma supernatant).
Polymerase chain reaction (PCR) analysis using the same primers as published for T-antigen LT1 and LT3 was performed on formalin-fixed, paraffin-embedded tissue blocks from the patient's primary nasopharyngeal tumor and lymph node metastasis ( Figure 2 ). 14, 16, 17 PCR was performed using the ApliTaq Gold (ABI), dNTP at 200 mM, primers at 200 nM in 25 mL volume. The cycling conditions were 95°C for 10 minutes, 35 cycles consisting of 30 s at 94°C, 30 s at 55°C, and 30 s at 72°C, then 72°C for 7 minutes. The b-globin (a housekeeping gene) product was run as a control, indicating the presence of intact amplifiable DNA. MCPyV was detected in the primary tumor and metastasis from 200 ng of genomic DNA extracted from formalin-fixed, paraffin-embedded specimens.
Discussion
We report a case of nasopharyngeal MCC with MCPyV detected by PCR in the primary tumor and in a lymph node metastasis. Primary nasopharyngeal MCC and metastasis also demonstrated strong immunostaining for CM2B4, a recently described antibody against MCPyV. A thorough history, clinical examination, and radiographic work-up revealed no cutaneous or bronchial tumor, only a nasopharyngeal mass with associated right inguinal lymph node metastasis. To the best of our knowledge, there have only been 2 reported cases of MCC oropharyngeal metastasis, and both patients had a known primary skin tumor. 18, 19 Our report adds to the recent literature supporting a role of and for MCPyV in MCC oncogenesis. 
-- The early clinical features of MCC are not specific. The tumor may be confused with other primary tumors, such as cutaneous carcinomas with basaloid features, metastatic small-cell carcinoma of the lung, or lymphoid neoplasms. 7, [20] [21] [22] Immunohistochemical stains aid in resolving the differential diagnoses and a complete immunohistochemical profile, including dot-like pattern staining with cytokeratins AE1/AE3 and CK20, is needed. Our primary tumor and metastasis were positive for CK20, cytokeratins AE1/AE3, and chromogranin and negative for LCA, S-100, CD99, TTF-1, and CK7. This immunohistochemical profile is characteristic of MCC. We also saw positive staining for TdT and C-KIT. TdT expression was previously reported in 8 of 15 cases of MCC. 22 C-KIT immunopositivity is largely variably found in MCC and is likely a result of heat-induced antigen retrieval. 23 Little is known of the molecular basis of MCC. Van Gele et al 24 performed comparative genomic hybridization of 34 specimens from 24 patients. Their work showed a pattern of gains and losses that closely resembled that seen in small-cell lung cancer. One of the most frequently observed losses involved the entire chromosome 10 or partial loss of the chromosome 10 long arm, which harbors the Mutated in Multiple Advanced Cancers 1 (MCCAC1) and PTEN tumor-suppressor genes. The common loss of 3p suggests that the tumor suppressor genes located on 3p, including the von Hippel-Lindau gene, the b-catenin gene, and the FHIT gene, are involved. Gains on 3q (present in 33% of cases) may involve certain proto-oncogenes such as LAZ3 and bcl-6, whereas gains on 8q and 19p (seen in 38% and 63%, respectively) may amplify MYCC and EEN oncogenes.
Lassacher et al 6 examined 21 MCCs for the presence of gene mutations commonly found in other forms of skin cancer. Their study showed no mutations in Ha-Ras, Ki-Ras, N-Ras, c-kit, or p14ARF. Methylation of p14ARF, which encodes p16, was common. Because DNA methylation in promoter regions helps regulate gene silencing and expression, the authors suggested that p14ARF silencing may be important in MCC tumorigenesis, thereby, highlighting a potential target for therapeutic intervention. 6 TP53 is rarely mutated, and no activating mutations in exons 1 and of the H-ras, K-ras, and N-ras genes were detected in 6 MCC cell lines. 25 Swick et al 26 found that 3 of 9 MCCs demonstrated an identical novel single heterozygous base change in exon 10 of the platelet-derived growth factor receptor a (PDG-FRA) gene, leading to an amino acid substitution at codon 478. All 3 of the MCCs expressed PDGFRA. This mutation may be oncogenic in nature and may make imatinib mesylate a possible therapeutic option in some MCCs. Another study by Swick et al 27 determined that no activating C-KIT mutations were present in the 4 most commonly mutated exons. Similarly, Kartha and Sundram 28 documented silent mutations in exon 17 of KIT and exons 10, 12, and 18 of PDGFRA but did not identify any known activating mutations.
Overexpression of antiapoptotic proteins, bcl-2, and survivin was described in MCCs. 29, 30 Cases with a nuclear staining pattern had an aggressive clinical course, with 7 of 8 patients developing metastases or found dead of disease on follow-up. Cases with cytoplasmic localization were free of disease on follow-up. Nuclear subcellular localization of survivin in MCC may portend a poor prognosis.
Others have corroborated the original observation of Feng et al 14 and have expanded on the role of viral oncogenesis in MCC. For example, MCPyV was reported in 16 of 37 MCC cases, with detection higher in tumors originating from North America (11 of 16) than from Australia (5 of 21). 10 Furthermore, MCPyV-associated MCC appears to arise from a 2-step process: first with viral genome integration followed by LT-antigen mutation to prevent autonomous viral genome replications. 31 MCPyV-positive tumor cells undergo selection for mutations truncating the product of the large T-antigen. The spliced viral transcripts target tumor suppressor and cell cycle regulatory proteins, promoting carcinogenesis.
The discovery of MCPyV in MCC has prompted investigation of the role of MCPyV in other cutaneous neoplasms. Sastre-Garau et al 32 A recent article by Busam et al 34 examined 17 cases of cutaneous MCC and analyzed them with a novel monoclonal antibody, CM2B4, that was generated against the predicted antigenic epitope on the MCPyV T-antigen. The CM2B4 antibody stained the majority of PCR-positive tumors (77%), and the specificity of labeling was high, but the sensitivity was less than qPCR (67% vs 88%, respectively). Additionally, a tissue microarray consisting of 36 MCCs, 7 combined squamous and neuroendocrine carcinomas of the skin, and 26 pulmonary endocrine carcinomas were examined with this antibody. A total of 32 of the 36 (89%) MCCs expressed CK20, and 27 (75%) were also immunoreactive for CM2B4. Pulmonary neuroendocrine tumors and skin tumors with a combined squamous and neuroendocrine phenotype failed to react with CM2B4.
Our study supports the role of MCPyV in the oncogenesis of MCC. Its presence in distant metastasis suggests stable integration of viral DNA. The clear confirmation that most MCC tumors carry MCPyV sequences represents an important first step in designating targeted therapies for this highly aggressive cancer.
